Salud financiera de hoja de balance de Bavarian Nordic

Salud financiera controles de criterios 6/6

Bavarian Nordic tiene un patrimonio de accionistas total de DKK9.7B y una deuda total de DKK18.0M, lo que sitúa su ratio deuda-patrimonio en 0.2%. Sus activos y pasivos totales son DKK15.0B y DKK5.3B respectivamente. El BAIT de Bavarian Nordic es de DKK1.3B, por lo que su ratio de cobertura de intereses es de -67. Tiene efectivo e inversiones a corto plazo que ascienden a DKK1.4B.

Información clave

0.2%

Ratio deuda-patrimonio

kr.17.98m

Deuda

Ratio de cobertura de intereses	-67x
Efectivo	kr.1.39b
Patrimonio	kr.9.69b
Total pasivo	kr.5.31b
Activos totales	kr.14.99b

Actualizaciones recientes sobre salud financiera

No hay actualizaciones

Recent updates

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (DKK4.4B) de BV3 superan a sus pasivos a corto plazo (DKK2.9B).

Pasivo a largo plazo: Los activos a corto plazo de BV3 (DKK4.4B) superan a sus pasivos a largo plazo (DKK2.4B).

Historial y análisis de deuda-patrimonio

Nivel de deuda: BV3 tiene más efectivo que su deuda total.

Reducción de la deuda: El ratio deuda-patrimonio de BV3 ha pasado de 30.6% a 0.2% en los últimos 5 años.

Cobertura de la deuda: La deuda de BV3 está bien cubierta por el flujo de caja operativo (3157.5%).

Cobertura de intereses: BV3 gana más intereses de los que paga, por lo que la cobertura de pagos de intereses no es preocupante.

Salud financiera de hoja de balance de Bavarian Nordic

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

Recent updates

Laurence De Moerlooze to Leave Bavarian Nordic A/S as Executive Vice President and Chief Medical Officer

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2024

Bavarian Nordic A/S Initiates Rolling Submission of Biologics License Application with FDA for Chikungunya Vaccine Candidate

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Switzerland

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2024

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Bavarian Nordic A/S's Mpox Vaccine Receives Recommendation from U.S. CDC Advisory Committee for Routine Use in Adults at Risk

Bavarian Nordic A/S Reports Additional Phase 3 Results and Provides Update on Development Program for its cVLP-Based COVID-19 Booster Vaccine Candidate, ABNCoV2

Bavarian Nordic A/S, Annual General Meeting, Apr 16, 2024

Bavarian Nordic A/S Provides Update on RSV Vaccine Program

Bavarian Nordic A/S Reports Data from A Phase 3 Clinical Trial of Its Vlp-Based Chikungunya Virus Vaccine in Adults >=65 Years of Age Study Successfully Met Its Primary Endpoints

Bavarian Nordic A/S Reports 12-Month Durability Data from Phase 2 Clinical Trial of Covid-19 Vaccine Candidate

Bavarian Nordic A/S acquired Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $384 million.

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Full year 2022 earnings released: kr.4.90 loss per share (vs kr.7.37 loss in FY 2021)

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S Provides Earnings Guidance for Fiscal Year 2023

Bavarian Nordic A/S Provides Revenue Guidance for Fiscal Year 2022

Bavarian Nordic Completes Enrollment in Global Phase 3 Trial of RSV Vaccine Candidate for Older Adults

Chairman recently sold €68k worth of stock

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: kr.0.20 (vs kr.1.30 loss in 3Q 2021)

Bavarian Nordic A/S Maintains Earnings Guidance for the Year 2022

Bavarian Nordic A/S Announces Covid-19 Booster Vaccine Candidate Demonstrates Durable Antibody Response Six Months After Vaccination in Phase 2 Clinical Trial

Bavarian Nordic A/S Appoints Luc Debruyne as Board of Directors

Bavarian Nordic A/S Revises Earnings Guidance for the Full Year 2022

Bavarian Nordic Announces Initiation of a Global Phase 3 Clinical Trial of its COVID-19 Booster Vaccine Candidate

Bavarian Nordic A/S, Annual General Meeting, Mar 30, 2023

Bavarian Nordic A/S to Report Fiscal Year 2022 Final Results on Mar 02, 2023

Second quarter 2022 earnings released: kr.3.40 loss per share (vs kr.2.40 loss in 2Q 2021)

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2022

Bavarian Nordic A/S Receives U.S. and Eu Approvals of Its Fill and Finish Vaccine Manufacturing Facility

Bavarian Nordic A/S Receives Positive CHMP Opinion on the Extension of Vaccine Label to Include Monkeypox

Bavarian Nordic A/S Raises Earnings Guidance for the Financial Guidance for 2022

Bavarian Nordic A/S Provides an Update on the Phase 3 Development of ABNCoV2, A VLP-Based, Non-Adjuvanted Covid-19 Booster Vaccine Candidate

Bavarian Nordic A/S Revises Revenue Guidance for the Year 2022

Bavarian Nordic A/S Raises Financial Guidance for the Year 2022

First quarter 2022 earnings released

Bavarian Nordic A/S Maintains Earnings Guidance for the Year 2022

Bavarian Nordic Reports Omicron Data from Phase 2 Trial of Its Covid-19 Booster Vaccine Candidate

Less than half of directors are independent

Bavarian Nordic Announces Initiation of A Global Phase 3 Clinical Trial of Its RSV Vaccine Candidate in Older Adults

Bavarian Nordic A/S Provides Revenue Guidance for the Full Year of 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Bavarian Nordic A/S Reports Additional Positive Phase 2 Results for Its Covid-19 Vaccine Candidate Ahead of Phase 3 Trial

Bavarian Nordic Announces Breakthrough Therapy Designation for Its RSV Vaccine Candidate for the Prevention of Respiratory Syncytial Virus in Older Adults

Bavarian Nordic Commits to Initiating Phase 3 Trial of RSV Vaccine Candidate and to Strengthening its Capital Base

Bavarian Nordic A/S announced a financing transaction

Executive Officer Tommi Kainu has left the company

High number of new directors

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Descubre empresas con salud financiera